Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2007;335:171 (28 July), doi:10.1136/bmj.39283.421007.1F
I was astounded to read in the study method that Hickson et al had excluded "high risk" antibiotics (as well as some misclassified low risk antibiotics).1 To do so is akin to performing a trial of an agent that claims to prevent type 2 diabetes, but excluding obese patients.
Cephalosporins in particular are rapidly losing their usefulness as frontline antimicrobial agents because of their potential to cause Clostridium difficile associated diarrhoea. The loss of these highly effective agents cannot be a good thing.
Any therapy that has the potential to reduce the incidence of diarrhoea associated with C difficile should be investigated with enthusiasm, but it should be done in a meaningful way. To exclude the very people in whom it is particularly important to prevent such diarrhoea—patients taking high risk antibiotics—makes this trial of academic value only.
Tom Billyard, Foundation year 2 doctor
University Hospitals Coventry and Warwickshire, Coventry CV2 2DX
tbillyard{at}doctors.org.uk